Compare Endeavour Silver Corp (EXK) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Nuvalent Inc — how do they compare? Endeavour Silver Corp trades at $7.59 (market cap $2.36B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 4.2× Endeavour Silver Corp's market cap, and Nuvalent Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| EXK | NUVL | |
|---|---|---|
Market Cap | $2.36B | $9.81B |
Sector | Basic Materials | Technology |
52-Week High | $14.12 | $123.96 |
52-Week Low | $4.96 | $72.16 |
Enterprise Value | $2.36B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $7.625, down 5.63% today, with a bearish technical signal from moving averages. The company reported a Q1 2026 earnings beat of $0.21 per share versus $0.10 expected, driven by record production. However, 2025 financials show a net loss of $119.1 million despite revenue growth, with negative profit margins and ROE. Analyst consensus is strongly bullish with 11 buy ratings.
Outlook hinges on operational execution and silver price trends. Investment opportunity exists from production growth and potential margin improvement, but risks include sustained negative profitability, high debt-to-asset ratio, and commodity price volatility. Cash flow trends show improvement into 2026, supporting near-term stability.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
